AVITA Medical Inc
NASDAQ:RCEL
AVITA Medical Inc
NASDAQ:RCEL
Price:
8.9 USD
1.71%
Market Closed
Updated:
May 7, 2024
AVITA Medical Inc
Cash from Financing Activities
|
AVITA Medical Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
AVITA Medical Inc
NASDAQ:RCEL
|
Cash from Financing Activities
$40.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is AVITA Medical Inc's Cash from Financing Activities?
Cash from Financing Activities
40.4m
USD
40.4m
USD
Based on the financial report for Dec 31, 2023, AVITA Medical Inc's Cash from Financing Activities amounts to 40.4m USD.
What is AVITA Medical Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
4 386%
4 386%
Over the last year, the Cash from Financing Activities growth was 4 386%.
You don't have any saved screeners yet
